Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more
Kangstem Biotech Co. Ltd (217730) - Total Liabilities
Latest total liabilities as of September 2025: ₩11.60 Billion KRW
Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) has total liabilities worth ₩11.60 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kangstem Biotech Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Kangstem Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kangstem Biotech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Kangstem Biotech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Star Holdings
NASDAQ:STHO
|
USA | $304.33 Million |
|
Sitowise Group Oyj
HE:SITOWS
|
Finland | €153.00 Million |
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
Vietnam | ₫6.88 Trillion |
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
Korea | ₩739.61 Billion |
|
Fursys
KO:016800
|
Korea | ₩58.87 Billion |
|
Empresas Tricot S.A
SN:TRICOT
|
Chile | CL$195.83 Billion |
|
Nibe Limited
NSE:NIBE
|
India | ₹1.78 Billion |
|
Resimac Group Ltd
AU:RMC
|
Australia | AU$16.49 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Kangstem Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kangstem Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kangstem Biotech Co. Ltd (2015–2024)
The table below shows the annual total liabilities of Kangstem Biotech Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩12.80 Billion | -65.15% |
| 2023-12-31 | ₩36.74 Billion | +10.21% |
| 2022-12-31 | ₩33.33 Billion | -4.97% |
| 2021-12-31 | ₩35.07 Billion | +13.56% |
| 2020-12-31 | ₩30.89 Billion | -28.04% |
| 2019-12-31 | ₩42.92 Billion | +68.30% |
| 2018-12-31 | ₩25.50 Billion | +13.65% |
| 2017-12-31 | ₩22.44 Billion | -8.27% |
| 2016-12-31 | ₩24.46 Billion | +553.16% |
| 2015-12-31 | ₩3.75 Billion | -- |